Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA

K-Number: K200676 · 2020-07-08

Decision Date2020-07-08
Product CodeEBG
Advisory CommitteeDE
DecisionSubstantially Equivalent

Device Summary

ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA is a medical device manufactured by Zirkonzahn Srl. It received FDA 510(k) clearance on 2020-07-08 under approval number K200676. The device is classified under product code EBG. It was reviewed by the DE advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA?

ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA is a medical device that received FDA 510(k) clearance on 2020-07-08. It is manufactured by Zirkonzahn Srl. The 510(k) number is K200676.

When was ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA approved by the FDA?

ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA received FDA 510(k) clearance on 2020-07-08, under approval number K200676.

What company makes ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA?

ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA is manufactured by Zirkonzahn Srl.

What is the FDA product code for ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA?

The FDA product code for ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA is EBG.

Other Devices by Zirkonzahn Srl

View all 7 devices →

Related Devices (Code: EBG)

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.